The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2019 Post San Antonio Breast Cancer Review
17:37

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer: Outcomes of DS-8201 Trial on Pts Previously Treated With T-DM1 & NALA Trial on Neratinib

FEATURING William Gradishar
  • 199 views
  • March 12, 2020
11:53

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Metastatic HER2+ Breast Cancer Management: Outcomes of HER2CLIMB Trial on Tucatinib & SOPHIA Trial on Margetuximab

FEATURING William Gradishar
  • 1,294 views
  • March 12, 2020
  • 6
10:29

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Adjuvant Therapy Options for HER2+ Breast Cancer: Outcomes of KATHERINE, APHINITY & ATEMPT Trials, De-escalation Strategies Will Dominate

FEATURING William Gradishar
  • 1,304 views
  • March 12, 2020
  • 4
18:55

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on Early Stage TNBC: 5-FU Has a Benefit, Neoadjuvant IO Works for High Risk Patients

FEATURING Virginia Kaklamani
  • 345 views
  • March 12, 2020
  • 2
06:40

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Highlights on IO in mTNB: IMpassion130 Suggest PD-L1+ Pts Have Better Outcomes w/ Atezolizumab+Chemo, SAFIRO2-IMMUNO Suggests Durvalumab Improves OS

FEATURING Virginia Kaklamani
  • 197 views
  • March 12, 2020
09:08

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Breast Cancer Chemoprevention: Anastrozole Significantly Reduces Incidence by 49% In Postmenopausal Women

FEATURING Terry Mamounas
  • 25 views
  • March 12, 2020
23:29

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Early Stage HR+: Oral Formulation S-1 + Adjuvant ET Improves Outcomes, Younger Women Derive More Benefit from Adjuvant Chemotherapy

FEATURING Terry Mamounas
  • 20 views
  • March 12, 2020
07:01

KU 2019 Post San Antonio Breast Cancer Review

SABCS 2019 Updates on Metastatic HR+ BC: PEARL Suggests Treatment With Palbociclib + ET Is Generally Better Tolerated Than Capecitabine

FEATURING Terry Mamounas
  • 240 views
  • March 12, 2020
  • 2
11:46

KU 2019 Post San Antonio Breast Cancer Review

52 y/o With HER2+/HR- De-novo Metastatic BC / 52 y/o With T2N0 HR+/HER2- Grade II IDC

FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
  • 18 views
  • March 12, 2020
11:23

KU 2019 Post San Antonio Breast Cancer Review

46 y/o F With Grade 2, 2.5 cm, NO ER+ Left BC / 40 y/o Premenopausal Woman With 5.5cm, Node Negative Grade IIDC / 48 y/o BRCA 2 Mutation Carrier With T2NO ER/PR+/HER2- BC

FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
  • 26 views
  • March 12, 2020
08:39

KU 2019 Post San Antonio Breast Cancer Review

55 y/o Diagnosed With T3NO TNBC / 42 y/o With cT2N+ Grade IlTNBC, Received Neoadjuvant Taxol/Carbo/Pembro

FEATURING Allison Kurian, Qamar Khan, Priyanka Sharma, Virginia Kaklamani, Terry Mamounas, William Gradishar
  • 13 views
  • March 12, 2020